

Applicant's Attorney submits the following amendments.

In the Claims

Add the following claims.

- Sub B22 ✓
71. A method of increasing p53 activity in a cell comprising contacting said cell with an effective amount of DNA fragments selected from the group consisting of: single-stranded DNA fragments, deoxynucleotides, dinucleotides, dinucleotide dimers and combinations thereof; wherein said fragments are about 2 to about 200 nucleotides in length.
- Sub C72 ✓
72. The method of Claim 71 wherein activation of p53 results in nucleotide excision repair in the cell.
73. The method of Claim 71 wherein the single-stranded DNA fragment is selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4.
74. The method of Claim 71 wherein the dinucleotides are selected from the group consisting of: d(pT)₂, d(pC)₂, d(pA)₂, d(pCpT), d(pTpC), d(CpT), d(TpC) and d(TpT).
- Sub B23 ✓
75. A method of treating hyperproliferative disease affecting epithelial cells in a mammal, comprising administering to the epithelial cells of interest in the mammal an effective amount of DNA fragments selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 and combinations thereof.
76. The method of Claim 75, wherein said DNA fragments are ultraviolet-irradiated.

77. The method of Claim 75, wherein the DNA fragments are administered in a delivery vehicle.
78. The method of Claim 77, wherein the delivery vehicle comprises liposomes.
79. The method of Claim 77, wherein the delivery vehicle comprises propylene glycol.
80. The method of Claim 75, wherein the DNA fragments are administered orally.
81. The method of Claim 75, wherein the DNA fragments are administered by aerosol.
82. The method of Claim 75, wherein the mammal is a human.
83. The method of Claim 75, wherein the epithelial cells of interest are carcinoma cells.
84. A method of treating allergically mediated inflammation selected from the group consisting of: atopic dermatitis, contact dermatitis allergic rhinitis and allergic conjunctivitis in a mammal, comprising administering topically to the epithelia of the mammal an effective amount of DNA fragments selected from the group consisting of: single-stranded DNA fragments, deoxynucleotides, dinucleotides, dinucleotide dimers and combinations thereof; wherein said DNA fragments are about 2 to about 200 nucleotides in length.
85. A method of inhibiting proliferation of skin cells in a mammal, comprising administering topically to the epidermis of the mammal an effective amount of DNA fragments selected

Sub B25

from the group consisting of: single-stranded DNA fragments, deoxynucleotides, dinucleotides, and dinucleotide dimers and combinations thereof wherein said DNA fragments are about 2 to about 200 nucleotides in length.

- ✓ A1
86. A method of preventing or reducing DNA damage in a cell, wherein said DNA damage is caused by UV irradiation or DNA-damaging chemicals, comprising contacting said cell with an effective amount of DNA fragments selected from the group consisting of: single-stranded DNA fragments, deoxynucleotides, dinucleotides, and dinucleotide dimers and combinations thereof; wherein said DNA fragments are about 2 to about 200 nucleotides in length.

- ✓ B
87. A composition comprising a DNA fragment comprising SEQ ID NO: 1 and a delivery vehicle.

- Sub B26
88. A method of treating malignant cells of a mammal, comprising contacting said cells with an effective amount of DNA fragments selected from the group consisting of: single-stranded DNA fragments, deoxynucleotides, dinucleotides, and dinucleotide dimers and combinations thereof; wherein said DNA fragments are about 2 to about 200 nucleotides in length.

- Sub C1
89. The method of Claim 85, wherein said skin cells are selected from the group consisting of: epithelial cells, melanocytes, keratinocytes and fibroblasts.

- ✓ B
90. A composition comprising a DNA fragment comprising SEQ ID NO: 2 and a delivery vehicle.

- ✓ 91. A composition comprising a DNA fragment comprising SEQ ID NO: 3 and a delivery vehicle.
- ✓ 92. A composition comprising a DNA fragment comprising SEQ ID NO: 4 and a delivery vehicle.

In the Specification

- ✓ On page 11, line 16, delete the prime symbol --- ' --- following the five in the phrase "oligonucleotides of 5' nucleotides."
- ✓ On page 12, line 2, insert a comma following "proliferation."
- ✓ On page 37, line 5, from the phrase "SEQ ID NOS: 1, 4, 6, 7" delete ---4, 6, 7---, and substitute therefor ---7, 4---.

Please insert the attached "Sequence Listing" (sheets 1/3 through 3/3), and comprising SEQ ID NOS: 1-12, into the above-referenced application.

REMARKS

The amendments to the written description have been made to comply with 37 C.F.R. §1.821 and to correct inadvertent errors.

Claims 71-92 have been added. Claims 72-74 and 77-83 are, respectively, originally filed Claims 2-4 and 11-17 of parent application 09/048,927 filed March 26, 1998. For Claim 75, support can be found in the written description on page 7, lines 17-19, page 15, lines 9-16 and page 16, lines 2-28. For Claim 76, support is found on page 9, lines 8-11, for example. Support for Claim 84 is found on page 10, lines 3-21, page 17, lines 1-15, and in Example 10, page 33, line 8 to page 34, line 12. Support for Claim 85 is found on page 7, lines 10-17, page 9, lines 12-19, page 17, lines 24-28, page 18, lines 15-20, and in Examples 4-6, page 23, line 1 to page 25, line 5. Support for Claim 86 is found on page 9, lines 22-27, page 12, lines 1-5 and lines 12-21,